arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Beam Therapeutics Inc.

BEAM

$24.68 ▲ +0.31 (+1.27%) at close

8 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Beam Therapeutics Inc. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.4B

Dividend Yield —

Revenue Growth 120.0% ↗

Op. Margin -274.6%

ROIC -31.0% ↗

FCF / Share $-3.64 ↗

Trailing P/E —

Price / Book 2.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 24, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$139.74M

↑ +120.0% —

Net Income Profit after all expenses

$-79.99M

↑ +78.8% —

Operating Margin Operating profit as % of sales

-274.6%

↓ -487.6% 0th

FCF / Share Free cash flow per share

$-3.64

↑ +15.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	120.0% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1400%)	-83.2% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1140%)	520.0% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+6400%)	17.5% Good ↓ Good Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+119%)	215916.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2698858%)	33.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+317%)	—	—
EPS Growth YoY (%)	82.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-166.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	58.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	28.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-37.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	70.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	78.8% Excellent ↑ Excellent Improving Year-over-year change in net income	-184.3% Weak ↓ Weak Declining Year-over-year change in net income	54.2% Excellent ↑ Excellent Improving Year-over-year change in net income	22.0% Good ↑ Good Improving Year-over-year change in net income	-90.5% Weak Weak Year-over-year change in net income	-148.4% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	15.9% Good ↑ Good Improving Year-over-year change in free cash flow	-82.5% Weak ↑ Weak Improving Year-over-year change in free cash flow	-528.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	78.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	26.6% Excellent Excellent Year-over-year change in free cash flow	81.6% Excellent Excellent Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	31.9% Excellent ↓ Excellent Declining Compound annual revenue growth over 3 years	7.0% Fair ↓ Fair Declining Compound annual revenue growth over 3 years	2406.0% Excellent Excellent Compound annual revenue growth over 3 years	1401.4% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	466.3% Excellent Excellent Compound annual revenue growth over 5 years	412.3% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Operating Margin (%) (%)	-274.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1930%)	—	-46.7% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-412%)	—	—	—	—	—
Effective Tax Rate (%) (%)	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	-1.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
Profit Margin (%) (%)	-57.2% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-577%)	—	-35.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-392%)	-474.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4054%)	—	—	—	—
FCF Margin (%) (%)	-257.7% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	—	-48.4% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-43.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-218.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—
FCF / Net Income (x)	4.50x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.38x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.09x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.31x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.58x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.08x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-31.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-56.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-14.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-46.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-47.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-42.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	29.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-25.9% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-37.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-12.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-25.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-26.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-29.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-6.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-143%)	-51.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-442%)	-13.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-190%)	-39.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-363%)	-44.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-399%)	-79.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-628%)	38.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+160%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Interest Coverage (x)	—	-12986.50x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1103.03x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-900.21x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-692.18x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-236.65x Weak Weak Operating income divided by interest expense Optimal: > 5x	-401.89x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-294.94M	$-281.97M	$-435.89M	$-232.77M	$-559.99M	$-162.17M	$-37.22M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$1.41	$0.77	$4.90	$0.87	$0.81	$0.00	$0.00	—
Basic EPS, GAAP (USD)	$-0.81	$-4.58	$-1.72	$-4.13	$-5.77	$-4.19	$-14.05	—
Free Cash Flow per Share (USD)	$-3.64	$-4.33	$-2.37	$-0.38	$-1.76	$-2.40	$-13.04	—
Book Value per Share (USD)	$12.17	$8.77	$12.02	$10.29	$12.09	$4.29	$-31.04	—
Tangible Book Value per Share (USD)	$12.17	$8.77	$12.02	$10.29	$12.09	$4.29	$-31.04	—
Basic Weighted Avg Shares (shares)	98.91M	82.31M	77.15M	70.02M	64.23M	46.73M	6.48M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$1.17B	$696.08M	$1.01B	$869.30M	$1.06B	$205.98M	—	—
Total Equity (USD)	$1.24B	$733.54M	$981.33M	$733.47M	$826.74M	$245.56M	$-201.10M	$-117.41M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$139.74M	$63.52M	$377.71M	$60.92M	$51.84M	$24.00K	$18.00K	—
Depreciation Expense (USD)	$22.29M	$21.93M	$20.01M	$14.15M	$7.45M	$4.74M	$3.50M	—
Net Income, GAAP (USD)	$-79.99M	$-376.74M	$-132.53M	$-289.09M	$-370.64M	$-194.59M	$-78.33M	—
Operating Cash Flow (USD)	$-345.10M	$-347.25M	$-149.19M	$22.53M	$-66.27M	$-95.74M	$-72.00M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 8 years · 31 quarters

Beam Therapeutics Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BEAM with peers